elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Epirubicin
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Epirubicin
RIS
0.001
(Research Intensity Score)
Papers
87
Top papers
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
2019 · 2619 citations
Metabolic Targeting of Oxidative Phosphorylation Enhances Chemosensitivity in Triple-Negative Breast Cancer via a Synergistic Nanomedicine
2025 · 52 citations
Hybridized quantum dot, silica, and gold nanoparticles for targeted chemo-radiotherapy in colorectal cancer theranostics
2024 · 66 citations
Tumor vessel-adaptable adhesive and absorbable microspheres for sustainable transarterial chemoembolization therapy
2025 · 28 citations
Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial
2025 · 20 citations
Chemotherapy for advanced gastric cancer
2017 · 1300 citations
Platinum-based systematic therapy in triple-negative breast cancer
2022 · 87 citations
Ultrasensitive Upconversion Nanoparticle Immunoassay for Human Serum Cardiac Troponin I Detection Achieved with Resonant Waveguide Grating
2024 · 29 citations
Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis
2025 · 8 citations
Newest papers
KẾT QUẢ ĐIỀU TRỊ BỔ TRỢ UNG THƯ BÀNG QUANG NÔNG BẰNG EPIRUBICIN NỘI BÀNG QUANG TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN
2026
Pseudomyogenic hemangioendothelioma (involving skin, bone and soft tissue): a case report with long-term follow-up and review of literature
2026
Capsaicin enhances chemosensitivity and mitigates MMP11-driven aggressiveness in human bladder cancer
2026
MIL-100(Fe)-Magnetite-Chitosan nanocomposite for targeted EPR delivery: synthesis, characterization, and DFT insights
2026
Metabolic Targeting of Oxidative Phosphorylation Enhances Chemosensitivity in Triple-Negative Breast Cancer via a Synergistic Nanomedicine
2025 · 52 citations
Tumor vessel-adaptable adhesive and absorbable microspheres for sustainable transarterial chemoembolization therapy
2025 · 28 citations
Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial
2025 · 20 citations
Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis
2025 · 8 citations
Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial
2025 · 5 citations
Browse all papers →
Epirubicin's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Epirubicin's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link